Ambe Medical Group Works in Partnership With NHS and Continues to Help and Support People Suffering With Diabetes

LONDON, June 15, 2012 /PRNewswire/ --

- Price of Blood Glucose Test Strips to the NHS to be cut by 50%

A dramatic price reduction by Ambe Medical Group has started to herald a big change in diabetes management and NHS strategy. The price of test strips has long been an issue for discussion. Somewhere in the region of 346 million people worldwide now have diabetes, publishes the WHO. The NHS is struggling with ever increasing costs. The charity, Diabetes UK has analysed official figures and calculated the NHS is now spending 10% of its annual budget on treating diabetes. A major component of these costs is test strips, with many- primary care trusts (PCT's) spending nearly as much on test strips as they do on medications to treat the disease.

New generations of treatments including colorimetric blood glucose test Glucoflex-R (pip code 346-8360) are now readily available on prescription to people with diabetes (Distributed in the UK by Ambe Medical Group). The introduction of this medical device is beneficial to both the patient and the NHS (for control and monitoring purposes for Blood Glucose Testing) which not only provides the care and output a patient requires but is also a cost effective solution to the NHS. An approximate saving against all other devices by 50% as its listed NHS reimbursement price is £7.40 (The most cost effective device on prescription within the UK).

PCT's in the north of England such as Leicester PCT have led the way by example and have started to switch patients over to Glucoflex-R saving the NHS millions  with absolutely no detrimental effect to the patient whatsoever.

Ambe Medical Group (UK Pharmaceutical Company based in Edenbridge, Kent) is aware that people all over the UK suffering with diabetes, on occasions, may find it difficult to access the medication, treatment and medical devices they need to manage their diabetes successfully. In order to reduce the impact of diabetes on the individual and the NHS, 'early and effective treatment is needed' advises Commercial Director Mr Patrick O'Neill-Ortiz. To this patients should, in consultation with their healthcare team, be able to choose the treatment which best controls their diabetes and the best quality of life.

PCTS's up north have started to implement this effective strategy, how long before other PCT's follow suit remains to be seen.